Alto Neuroscience (ANRO) Accumulated Expenses (2023 - 2026)
Alto Neuroscience (ANRO) posted Accumulated Expenses of $7.6 million for Q1 2026, down 14.13% sequentially from $8.9 million in Q4 2025, and up 29.58% YoY from $5.9 million in Q1 2025.
Alto Neuroscience (ANRO) Accumulated Expenses (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Accumulated Expenses for 4 years, with the latest figure at $7.6 million in Q1 2026.
- Quarterly Accumulated Expenses rose 29.58% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 29.58% YoY) and the FY2025 annual result came in at $8.9 million, up 5.14% from the prior year.
- Accumulated Expenses eased to $7.6 million in Q1 2026 per ANRO's latest filing, from $8.9 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $8.9 million in Q4 2025 and troughed at $4.4 million in Q1 2024.
- A 4-year average of $6.7 million and a median of $6.7 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 85.82% in 2024, then fell 15.16% in 2025.
- Over 4 years, Accumulated Expenses stood at $4.5 million in 2023, then soared by 85.82% to $8.4 million in 2024, then climbed by 5.14% to $8.9 million in 2025, then dropped by 14.13% to $7.6 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $7.6 million, $8.9 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.86 Mn |
| Mar 31, 2026 | 7.61 Mn |
| Dec 31, 2025 | 8.86 Mn |
| Sep 30, 2025 | 6.99 Mn |
| Jun 30, 2025 | 6.46 Mn |
| Mar 31, 2025 | 5.87 Mn |
| Dec 31, 2024 | 8.43 Mn |
| Sep 30, 2024 | 8.23 Mn |
| Jun 30, 2024 | 5.68 Mn |
| Mar 31, 2024 | 4.45 Mn |
| Dec 31, 2023 | 4.54 Mn |